Company intelligence / Profile preview

InfiniteVision Optics

Strasbourg, Grand Est, Francepmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

The company has developed the PreciSight® intraocular lens system, which received CE-mark approval in December 2017. This device allows for minimally invasive adjustment of the front optic component after implantation to address changes in vision over a patient’s lifetime. The technology reduces risks associated with full explantation and provides surgeons with flexibility to optimize refractive outcomes for cataract and corneal transplant patients.

Therapeutic areas: Ophthalmology
Modalities: Device (specifically intraocular lens system)
Industry: Implantable Medical Devices

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on InfiniteVision Optics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InfiniteVision Optics.

Explore the full profile